A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants
- 28 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 44 (3), 291-312
- https://doi.org/10.1007/s40264-020-01027-x
Abstract
Introduction Antidepressant use during the first trimester is reported in 4-8% of pregnancies. The use of some selective serotonin reuptake inhibitors during the first trimester has been identified as increasing the odds for congenital heart defects; however, little is known about the safety of non-selective serotonin reuptake inhibitor antidepressants. Objective The objective of this study was to assess the odds of congenital heart defects associated with the use of antidepressants during the first trimester of pregnancy, and to update the literature as newer studies have been published since the latest systematic literature review and meta-analysis. Methods PubMed and Embase were searched till 3 June, 2020. Study quality was assessed, and study details were extracted. Meta-analyses were performed using RevMan 5.4, which assessed: (1) any antidepressant usage; (2) classes of antidepressants; and (3) individual antidepressants. Results Twenty studies were identified, encompassing 5,337,223 pregnancies. The odds ratio for maternal use of any antidepressant during the first trimester of pregnancy and the presence of congenital heart defects from the random effects meta-analysis was 1.28 (95% confidence interval [CI] 1.17-1.41). Significant odds ratios of 1.69 (95% CI 1.37-2.10) and 1.25 (95% CI 1.15-1.37) were reported for serotonin norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors, respectively. A non-statistically significant odds ratio of 1.02 (95% CI 0.82-1.25) was reported for the tricyclic antidepressants. Analyses of individual SSRIs produced significant odds ratios of 1.57 (95% CI 1.25-1.97), 1.36 (95% CI 1.08-1.72), and 1.29 (95% CI 1.14-1.45) for paroxetine, fluoxetine, and sertraline, respectively. The norepinephrine-dopamine-reuptake inhibitor bupropion also produced a significant odds ratio of 1.23 (95% CI 1.01-1.49). Conclusions The selective serotonin reuptake inhibitor and serotonin norepinephrine reuptake inhibitor classes of antidepressants pose a greater risk for causing congenital heart defects than the tricyclic antidepressants. However, this risk for individual antidepressants within each class varies, and information regarding some antidepressants is still lacking.Keywords
This publication has 50 references indexed in Scilit:
- Testing the Newcastle Ottawa Scale showed low reliability between individual reviewersJournal of Clinical Epidemiology, 2013
- Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort StudyPLOS ONE, 2013
- Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studyBMJ Open, 2012
- Pregnancy Outcome After Exposure to Antidepressants and the Role of Maternal DepressionJournal of Clinical Psychopharmacology, 2012
- Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008American Journal of Obstetrics and Gynecology, 2011
- Study types and bias—Don’t judge a study by the abstract’s conclusion aloneEvidence-Based Spine-Care Journal, 2010
- Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisClinical Epidemiology, 2010
- Selective serotonin reuptake inhibitors pathwayPharmacogenetics and Genomics, 2009
- Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational studyBritish Journal of Clinical Pharmacology, 2008
- Maternal use of selective serotonin re‐uptake inhibitors in early pregnancy and infant congenital malformationsBirth Defects Research Part A: Clinical and Molecular Teratology, 2007